SGLT2 inhibition with empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 21% (HR 0.79, 95% CI 0.69–0.90, p < 0.001), which was independent of the presence or absence of diabetes. The gene discussed is SLC5A2; the disease is heart failure.